Bal Pharma Ltd. (BSE: 524824) is a Bengaluru, Karnataka-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹153 Cr, it ranks #2,897 by market cap among the 6,137 Indian listed companies on FinBizNet, and #60 of 86 in Medicinal Chemicals and Botanical Products. At ₹81.09 (as of 25 Oct 2026), the share price is 34.9% below its 52-week high of ₹124.60 and 35.2% above its 52-week low of ₹60.00. The share price is down 0.7% over one year and down 7.2% over three months.
| Current Price | ₹81.09 |
|---|---|
| Market Cap | ₹153 Cr |
| BSE Code | 524824 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 23.2 |
| Return on Equity | 7.92% |
| Return on Assets | 3.35% |
| 52-Week Range | ₹60.00 – ₹124.60 |
| 1-Year Price Change | -0.7% |
| 3-Month Price Change | -7.2% |
| Beta (1Y) | 0.68 |
| Dividend Yield | 1.31% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.balpharma.com |
| Revenue | ₹89 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 1.3% |
| EPS (Basic) | ₹0.71 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs f
1. Manufacturing of Pharmaceuticals-This segment engages in the manufacture and marketing of pharmaceutical formulations and active pharmaceutical ingredients in India. It offers prescription drugs, generics, OTC products, intravenous infusions, and bulk actives.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Bal Pharma Ltd. | ₹153 Cr | 23.2 | 7.92% | ₹89 Cr | -0.7% |
Listed by market capitalisation. Ratios are shown for context only.
Bal Pharma Ltd. is trading at ₹81.09, with a market capitalisation of ₹153 Cr.
Bal Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Bal Pharma Ltd. has a P/E of 23.2 and a return on equity of 7.92%.
Bal Pharma Ltd. is listed on the BSE under the scrip code 524824.
Bal Pharma Ltd.'s share price is down 0.7% over one year and down 7.2% over three months. Its 52-week range is ₹60.00 to ₹124.60.
In Q1 FY27, Bal Pharma Ltd. reported revenue of ₹89 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.71 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.